HOUSTON, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that senior management will participate in three upcoming healthcare investor conferences.
2019 Wells Fargo Securities Healthcare Conference
Date/Time: Wednesday, September 4, 2019 at 3:35 p.m. EDT
Citi’s 14th Annual Biotech Conference
Date: Thursday, September 5, 2019 (one-on-one investor meetings)
Ladenburg Thalmann 2019 Healthcare Conference
Date/Time: Tuesday, September 24, 2019 at 11:30 a.m. EDT
Location: New York
Live webcasts of the presentations at the Wells Fargo and Ladenburg Thalmann conferences may be accessed from the News & Events section of the Bellicum website. An archived version of each webcast will be available for replay immediately following the event.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T and allogeneic T cell therapies. Bellicum’s lead GoCAR-T® candidate, BPX-601, is designed to be a more efficacious CAR-T cell product capable of overriding key immune inhibitory mechanisms. Bellicum’s rivo-cel product candidate is an allogeneic polyclonal T cell therapy that has shown promising clinical trial results in reducing leukemia relapse after a stem cell transplant. For additional information about the company, please visit bellicum.com.
Robert H. Uhl
Senior Vice President